

NATIONAL DRUGGISTS (PROPRIETARY) LIMITED, SOUTH AFRICA

DIRECTORS REPORT

To the Members

Your Directors are pleased to present the Company's Annual Report for the year ended March 31, 2015.

Financial Results

Your Company is a wholly owned subsidiary of Ipca Laboratories Ltd (India). The business activity of the company is holding of product registration dossiers, importing and marketing of pharmaceuticals manufactured by the parent company in South Africa.

During the financial year under report, your Company had earned an income of ₹ Nil. (Previous year ₹ 0.02 lacs) and during the year under report the operations have resulted in a net loss of ₹ 0.36 lacs (Previous year net loss of ₹ 0.37 lacs).

Dividend

In view of the loss incurred during the financial year under report, no dividend is proposed by the directors.

Directors' Responsibility Statement

Your Directors confirm:

—
that in the preparation of the annual accounts, the applicable accounting standards have been followed along with proper explanation relating to material departures;

that your Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year March 31, 2015 and of the profit and loss of the Company for the year;

that your Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

that your Directors have prepared the annual accounts on a going concern basis.

that your Directors have laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and were operating effectively.

that your Directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

Particulars of Employees

During the year under review, the company had no employee.

Conservation of Energy, Technology Absorption and Foreign Exchange Earnings and Outgo and other related disclosures

During the year under review, the Company has not carried out any manufacturing activities nor the company has any manufacturing unit. This Company is incorporated outside India. Therefore, the above information required pursuant to the Companies Act, 2013 are not applicable.

For and on behalf of the Board



Murali Sarma

Chairman

May 30, 2015

NATIONAL DRUGGISTS (PROPRIETARY) LIMITED

Balance Sheet as at March 31, 2015

Particulars	Note Ref	(₹ Lakhs)	(₹ Lakhs)
		As at 31st March' 2015	As at 31st March' 2014
I EQUITY & LIABILITIES			
1 Shareholders' Funds			
(a) Share Capital	1	45.72	45.72
(b) Reserves & Surplus	2	(39.73)	(38.81)
(c) Money Received Against Share Warrants		-	-
		<u>5.99</u>	<u>6.91</u>
2 Share Application Money Pending Allotment		-	-
3 Non-Current Liabilities			
(a) Long-Term Borrowings		-	-
(b) Deferred Tax Liabilities (net)		-	-
(c) Other Long Term Liabilities		-	-
(d) Long Term Provisions		-	-
		<u>-</u>	<u>-</u>
4 Current Liabilities			
(a) Short-Term Borrowings		-	-
(b) Trade Payables	3	2.15	1.10
(c) Other Current Liabilities		-	-
(d) Short-Term Provisions	4	-	0.92
		<u>2.15</u>	<u>2.02</u>
		<u>8.14</u>	<u>8.93</u>
TOTAL			
II ASSETS			
1 Non-Current Assets			
(a) Fixed Assets			
(i) Tangible Assets		-	-
(ii) Intangible Assets		-	-
(iii) Capital Work-in-Progress		-	-
(iv) Intangible Assets Under Development		-	-
		<u>-</u>	<u>-</u>
(b) Non-Current Investments		-	-
(c) Deferred Tax Assets (net)		-	-
(d) Long-Term Loans & Advances		-	-
(e) Other Non-Current Assets		-	-
		<u>-</u>	<u>-</u>
2 Current Assets			
(a) Current Investments		-	-
(b) Inventories		-	-
(c) Trade Receivables		-	-
(d) Cash and Bank Balances	5	8.14	8.93
(e) Short-term loans and advances		-	-
(f) Other current assets		-	-
		<u>8.14</u>	<u>8.93</u>
		<u>8.14</u>	<u>8.93</u>
TOTAL			

Statement of Significant Accounting policies and Other Explanatory Notes form part of the Balance Sheet and Statement of Profit and Loss

For and on behalf of the Board

Place: Mumbai
Date: May 30, 2015


Murali Sarma
Chairman/Director


Manish Jain
Director

NATIONAL DRUGGISTS (PROPRIETARY) LIMITED
Statement of Profit and Loss for the year ended March 31, 2015

Particulars	Note Ref	(₹ Lakhs) 2014-15	(₹ Lakhs) 2013-14
Revenue			
I Revenue from Operations (Gross):			
Sale of products		-	-
Sale of Services		-	-
Other Operating Revenue		-	-
Less : Excise duty		-	-
II Other Income	6	-	0.02
III Total Revenue (I + II)		-	0.02
IV Expenses			
Cost of Materials Consumed		-	-
Purchase of Stock-in-Trade		-	-
Changes in inventories of finished goods, work-in-progress and Stock-in-Trade		-	-
Employee Benefit Expenses		-	-
Finance Cost		-	-
Depreciation & Amortisation		-	-
Other Expenses	7	0.36	0.39
Total Expenses		0.36	0.39
V Profit/(Loss) Before exceptional, extraordinary items and Tax (III-IV)		(0.36)	(0.37)
VI Exceptional Items		-	-
VII Profit/(Loss) Before extraordinary items and Tax (V-VI)		(0.36)	(0.37)
VIII Extraordinary Items		-	-
IX Profit/(Loss) Before Tax (VII-VIII)		(0.36)	(0.37)
X Tax Expense			
1. Current Tax		-	-
2. Deferred Tax		-	-
3. Tax Provision for earlier years		-	-
XI Profit/(Loss) After Tax (IX-X)		(0.36)	(0.37)
XII Earnings per Equity Share: (₹)	9		
Basic		(0.03)	(0.03)
Diluted		(0.03)	(0.03)
Par Value		Rand 1 each	Rand 1 each

Statement of Significant Accounting policies and Other Explanatory Notes form part of the Balance Sheet and Statement of Profit and Loss.

For and on behalf of the Board

Place: Mumbai
Date: May 30, 2015


Murali Sarma
Chairman/Director



Manish Jain
Director

NATIONAL DRUGGISTS (PROPRIETARY) LIMITED
Cash flow statement for the year ended 31st March 2015

Particulars	2014-15 (₹ Lakhs)	2013-14 (₹ Lakhs)
CASH FLOW FROM OPERATING ACTIVITIES		
1. Net profit/(loss) before taxation	(0.36)	(0.37)
2. Operating profit before working capital changes	(0.36)	(0.37)
Increase/(Decrease) in Trade Payables	1.05	0.30
3. Cash generated from operation	0.69	(0.07)
Income tax paid (Net)	(0.92)	-
Movement in Foreign currency translation reserve	(0.56)	(0.31)
Net cash from operating activities (A)	(0.79)	(0.38)
Net increase/(decrease) in cash and cash equivalents (A)	(0.79)	(0.38)
Cash and cash equivalents at beginning of period	8.93	9.31
Cash and cash equivalents at end of period	8.14	8.93
Components of Cash & Cash equivalents:		
Cash in hand	-	-
Balance with Banks	8.14	8.93
	8.14	8.93

For and on behalf of the Board

Place: Mumbai
Date: May 30, 2015


Murali sarma
Chairman/Director


Manish Jain
Director

Statement of Significant Accounting policies and Other Explanatory Notes

ACCOUNTING POLICIES

a) Accounting convention

The classification of assets and liabilities of the Company is done into current and non-current based on the operating cycle of the business of the Company. The operating cycle of the business of the Company is less than twelve months and therefore all current and non-current classifications are done based on the status of realisability and expected settlement of the respective asset and liability within a period of twelve months from the reporting date as required by Schedule III to the Companies Act, 2013.

The accounting policies adopted in the preparation of financial statements are consistent with those used in the previous year.

b) Conversion in to Indian Rupees:

The translation of financial statements into Indian Rupees is done in accordance with AS 11 (Revised) the Effects of Changes in Foreign Exchange Rates notified by the Companies (Accounting Standards) Rules 2006. The resultant Foreign Currency Translation Reserve is shown separately under Reserves and Surplus forming part of shareholders funds.

The Assets and Liabilities are translated at closing rate except share capital, which is translated at the rate as on transaction date. The income and expenditure are translated at a rate nearing the average rate during the year.

c) Investments: Long term Investments are stated at cost. Provisions are made for diminution in value of investments other than temporary in nature. Current Investments are stated at cost or market value whichever ever is lower.

d) Inventories: Inventories are valued on First in first out (FIFO) method at cost or net realizable value (NRV), whichever is lower.

e) Revenue Recognition:

i) Sales of goods is recognised at the point of dispatch to customer.

ii) Dividend Income: Dividend income is accounted when the right to receive the same is established.

f) Cash and Cash Equivalents: Cash and cash equivalents in the Balance Sheet comprise cash at bank, cheques on hand, cash in hand and short term investments with an original maturity of three months or less.

OTHER EXPLANATORY NOTES

1 SHARE CAPITAL

Face Value Class of Shares	31st March' 2015		31st March' 2014	
	No. of Shares	(₹ Lakhs) Rand 1 each	No. of Shares	(₹ Lakhs) Rand 1 each
Authorized Capital	1,100,000	-	1,100,000	-
Issued, Subscribed and Paid up Capital	1,059,732	45.72	1,059,732	45.72
PER BALANCE SHEET		<u>45.72</u>		<u>45.72</u>

Disclosures:

Reconciliation of number of shares

Particulars	As at 31 March 2015		As at 31 March 2014	
	No. of shares	(₹ Lakhs)	No. of shares	(₹ Lakhs)
Shares outstanding at the beginning of the year	1,059,732	45.72	1,059,732	45.72
Shares Issued during the year	-	-	-	-
Shares outstanding at the end of the year	<u>1,059,732</u>	<u>45.72</u>	<u>1,059,732</u>	<u>45.72</u>

Details of Shareholding in excess of 5%

Name of Shareholder	31st March' 2015		31st March' 2014	
	No. of shares	Percentage	No. of shares	Percentage
Ipca Laboratories Ltd	1,059,732	100	1,059,732	100

Particulars	31st March' 2015 (₹ Lakhs)	31st March' 2014 (₹ Lakhs)
-------------	-------------------------------	-------------------------------

2 RESERVES & SURPLUS

a) Other Reserve

Foreign Currency Translation Reserve

Balance as per last Balance Sheet	(10.90)	(10.63)
Add : Addition during the year	<u>(0.56)</u>	<u>(0.27)</u>
Balance as at year end	<u>(11.46)</u>	<u>(10.90)</u>

(Net exchange differences are accumulated in foreign currency translation reserve account)

b) Surplus

Balance as per last Balance Sheet	(27.91)	(27.54)
Add : Profit/(Loss) for the year	<u>(0.36)</u>	<u>(0.37)</u>
Balance as at year end	<u>(28.27)</u>	<u>(27.91)</u>

PER BALANCE SHEET	<u>(39.73)</u>	<u>(38.81)</u>
-------------------	----------------	----------------

3 TRADE PAYABLES

Trade Payables

- Others	<u>2.15</u>	<u>1.10</u>
----------	-------------	-------------

PER BALANCE SHEET	<u>2.15</u>	<u>1.10</u>
-------------------	-------------	-------------

The Company represents that in the country of its operation there is no requirement of classification of business enterprises as Micro, Small and Medium enterprises.

4 SHORT TERM PROVISIONS

Provision for Taxation	<u>-</u>	<u>0.92</u>
PER BALANCE SHEET	<u>-</u>	<u>0.92</u>

Particulars	31st March' 2015 (₹ Lakhs)	31st March' 2014 (₹ Lakhs)
5 CASH AND BANK BALANCES		
Cash & Cash Equivalents		
Balances with Banks	<u>8.14</u>	<u>8.93</u>
PER BALANCE SHEET	<u><u>8.14</u></u>	<u><u>8.93</u></u>

Particulars	2014-15 (₹ Lakhs)	2013-14 (₹ Lakhs)
6 OTHER INCOME		
Refund from revenue services	<u>-</u>	<u>0.02</u>
PER STATEMENT OF PROFIT & LOSS	<u><u>-</u></u>	<u><u>0.02</u></u>
7 OTHER EXPENSES		
Bank Charges	<u>0.04</u>	<u>0.04</u>
Audit fees	<u>0.32</u>	<u>0.35</u>
PER STATEMENT OF PROFIT & LOSS	<u><u>0.36</u></u>	<u><u>0.39</u></u>

8 Disclosure under AS -18 "Related Party Disclosure" as notified by the Companies (Accounting Standards) Rules 2006

Relationship	Country
Entities where control exists	
Ipca Laboratories Limited.- Holding company	India

9 Earning per Share

The earning per share is calculated by dividing the profit after tax by weighted average no. of shares outstanding for basic and diluted EPS.

Particulars	2014-15	2013-14
Profit after tax (₹ Lakhs)	(0.36)	(0.37)
Equity Shares Outstanding (Nos)		
-Opening	1,059,732	1,059,732
-Issued during the year	-	-
-Closing	1,059,732	1,059,732
Weighted Average no. of shares outstanding (Nos.) - Basic	1,059,732	1,059,732
Weighted Average no. of shares outstanding (Nos.) - Diluted	1,059,732	1,059,732
Nominal value of equity share	R 1 each	R 1 each
Earning per share (₹)		
- Basic	(0.03)	(0.03)
- Diluted	(0.03)	(0.03)

10 Prior period comparatives

Previous year's figures have been regrouped or rearranged wherever necessary to make them comparable.

11 The annual accounts have been prepared on going concern basis.

12 The Company is 100% subsidiary of Ipca Laboratories Limited. The accounts have been prepared and restated in Indian Rupees for the purpose of attachment to the accounts of the holding company to comply with the provisions of Indian Companies Act.

13 The Balance Sheet, Statement of Profit and Loss, Cash Flow Statement, Statement of significant accounting policy and other explanatory notes form an integral part of the financial statements of the company for the year ended on 31st March, 2015.

For and on behalf of the Board

Place: Mumbai
Date: May 30, 2015



Murali Sarma
Chairman/Director



Manish Jain
Director

24